Psoriasis Treatment Ustekinumab Reduces Vascular Inflammation
Ustekinumab improves psoriasis and reduces vascular inflammation among patients with moderate-to-severe psoriasis.
Ustekinumab improves psoriasis and reduces vascular inflammation among patients with moderate-to-severe psoriasis.
Results comparing treatments for scabies were presented at the 2018 American Academy of Dermatology Annual Meeting.
The efficacy and generally safe profile of upadacitinib supports advancing to a phase 3 trial.
Combined results from the UltIMMa-1 and UltIMMa-2 trials were presented at the 2018 American Academy of Dermatology Annual Meeting in San Diego.
Identifying risk of metastasis in patients with melanoma may help clinicians determine initial workup, referral patterns, and follow-up intervals.
Data from a preliminary placebo-controlled trial on ASN002 were presented at the 2018 American Academy of Dermatology Annual Meeting.